Boehringer Ingelheim withdraws libido drug for women

doi:10.1136/bmj.c5701

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ news articles:

From

The BMJ iPad app brings you the best of print and online, including live links to the latest news, blogs, video, and podcasts. Get the BMJ iPad app.
Countdown to London 2012: BMJ Group's Olympics portal highlights latest Olympics and sports medicine-themed research, comment and learning
Keep up to date with cardiology: Access the latest cardiovascular medicine resources from across BMJ Group.
Our online table of contents is updated at least twice each day. Read all articles published in the last 7 days.
OPEN ACCESS: All research articles are freely available online, with no word limit. Find out more about the BMJ's open access policy. Submit your paper.

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Jeanne Lenzer

¹New York

The German drug company Boehringer Ingelheim announced on 8 October that it is withdrawing from development its drug to increase female sexual desire.

The drug, flibanserin, which reduces serotonin concentrations while raising those of dopamine and noradrenaline (norepinephrine), was originally intended to be an antidepressant.

The company made the announcement after negative reviews by an advisory panel of the US Food and Drug Administration in June (BMJ 2010;341:c3339 doi:10.1136/bmj.c3339) and a letter issued by the agency in August in response to the company’s new drug application.

Boehringer Ingelheim conducted several studies of the drug in North America …